Menu
Recruiting NCT06648733

Improving Pharmacological Transition of Palliative Care Patients From Inpatient to Outpatient Care

No phase Interventional Cancer Heart Failure COPD

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Structured pharmaceutical discharge management.
Who it may be relevant to
Registry conditions: Cancer, Heart Failure, COPD. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Germany
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Improving Pharmacological Transition of Palliative Care Patients From Inpatient to Outpatient Care (Optimierung Der Pharmakologischen Überleitung Von Palliativpatient:Innen Von stationär Nach Ambulant)

Overview

The transition of palliative care patients from inpatient to outpatient care is aimed to be improved through structured pharmaceutical discharge management by a trained pharmacist. This data will be compared with retrospective cases.

Detailed description

As part of a prospective observational study with a retrospective comparison group, a pharmacist should, on request, check the discharge medication planned by the primary care physicians before discharge and discuss it with the various colleagues providing (follow-up) care. In addition, the availability in the outpatient "medicine cabinet" and the possibility of prescribing by the responsible GPs (by telephone) should be checked in advance. In addition, longitudinal focus groups with relevant stakeholders are to be conducted to collect quantitative data as well as qualitative data on the views of those providing and receiving treatment.

There will be cooperation with the Specialized Outpatient Palliative Care Service Muenster to ensure sufficient case numbers and a low rate of missing values through partial use of the standard care data from the "Information System Palliative Care" (ISPC) program they use.

Interventions

  • Other Structured pharmaceutical discharge management
    These patients will receive structured pharmaceutical discharge management from inpatient to outpatient care.

Primary outcome measures

  • (I) Drug-related problems [Time frame: 12 months]
  • (II) Drug-related problems [Time frame: 12 months]
Secondary outcome measures (12)
  • Number of contacts [Time frame: 12 months]
  • Number of readmissions / visits [Time frame: 12 months]
  • Symptom burden [Time frame: 12 months]
  • (I) Medication changes [Time frame: 12 months]
  • Adoption rate [Time frame: 12 months]
  • (I) GP contact [Time frame: 12 months]
  • (I) SOPC contact [Time frame: 12 months]
  • (I) Post-discharge medication changes [Time frame: 12 months]
  • Focus groups [Time frame: 12 months]
  • (I) Further parameters [Time frame: 12 months]
  • (II) Medication changes [Time frame: 12 months]
  • (II) GP contact [Time frame: 12 months]

Eligibility criteria

Inclusion criteria

All individual indications for general and specialised palliative care as part of routine clinical practice (e.g.):

  • advanced, malignant tumour disease
  • advanced, chronic obstructive pulmonary disease
  • Patients with advanced disease and limited life expectancy (approx. 12 months) Further care in the SOPC Muenster (prospective data) Sufficient understanding of the German language to be able to understand the information and consent form

Exclusion criteria

Impossibility of understanding the information and declaration of consent.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Non-randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Supportive care

Study locations

Germany · 1 center
  • University Hospital Muenster — Münster

Identifiers

NCT: NCT06648733 · 2024-258-f-S · 2025-131-BO

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗